ASCO 2022: Combination regimen improves overall survival in a type of newly diagnosed metastatic colorectal cancer

5 Jun 2022
ASCO 2022: Combination regimen improves overall survival in a type of newly diagnosed metastatic colorectal cancer

The use of panitumumab (Vectibix) plus mFOLFOX6 significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer that was classified as left-sided compared to patients who received mFOLFOX6, a standard chemotherapy regimen, plus bevacizumab (Avastin), a monoclonal antibody, according to a finding that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Patients with RAS wild-type (non-mutated) metastatic colorectal left-sided tumours who received panitumumab lived for 37.9 months from the start of treatment in the trial compared to 34.3 months for those who received bevacizumab; they had an 18% lower risk of death.

PFS, where tumour size was stable or shrinking, was 13.7 vs. 13.2 months, respectively, which was statistically equivalent in both groups.

The response rate, which is the percentage of patients with cancer that shrinks or disappears after treatment, and the curative resection rate, which indicates that no tumour remains in the body, were both higher with panitumumab compared to bevacizumab.

For OS in right-sided tumours, there was no statistically significant difference between panitumumab and bevacizumab.

Adverse events were consistent with those previously reported.

“This trial demonstrates that if gene testing shows that a tumour is RAS wild-type, the choice of initial treatment with panitumumab plus mFOLFOX6 chemotherapy is superior to initial treatment with bevacizumab plus mFOLFOX6 chemotherapy for those people with left-sided tumours.

It has long been believed that the sequence of metastatic colorectal cancer treatment does not matter as long as patients had access to the drugs at some point, which has now been disproven,” said lead author Takayuki Yoshino, PhD, who is the Chief for the Department of Gastrointestinal Oncology and the Deputy Director of the National Cancer Center Hospital East in Kashiwa, Japan.

In the U.S., an estimated 151,030 adults will be diagnosed with colorectal cancer in 2022.

If the cancer spreads to distant parts of the body, the 5-year survival rate is 15%.

About 22% of patients are diagnosed at this metastatic stage.

Panitumumab, approved for use in colorectal cancer by the U.S. Food and Drug Administration in 2006, is a human monoclonal antibody that targets the epidermal growth factor receptor (EGFR).

Bevacizumab is a monoclonal antibody drug that targets the VEGF receptor.

Modified FOLFOX6 (mFOLFOX6), is a combination chemotherapy regimen that includes the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.

No new drugs have demonstrated superior benefit over standard-of-care treatments for a decade in newly diagnosed metastatic RAS wild-type colorectal cancer.

Previous studies have retrospectively analysed data comparing anti-EGFR antibody drugs and bevacizumab.

Those studies did not provide consistent results.

However, PARADIGM is the largest study conducted to date to prospectively assess the impact of panitumumab in a randomized study that also assesses the impact of primary tumour location per sidedness.

Results of the study suggest tumour location, along with gene testing, should be part of standard disease assessment as it can impact treatment decision-making.

From May 2015 to June 2017, 823 patients in Japan were randomly assigned to one of two treatment arms in the PARADIGM phase III clinical trial.

Patients were followed for a median of 61 months.

A total of 400 patients received panitumumab and 402 patients received bevacizumab.

Both groups received mFOLFOX6.

There were 614 patients out of a total of 802 patients who had left-sided primary tumours.

The primary endpoint was OS.

Key secondary endpoints included PFS, response rate, and curative resection rate.

Left-sided colon cancers arise in the splenic flexure (where the colon bends near the spleen), the descending part of the colon, and/or the sigmoid colon and/or the rectum.

Right-sided colon cancers arise in the cecum, ascending colon, hepatic flexure, and/or transverse colon.

PARADIGM was funded by Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Ltd., Tokyo, Japan.

A large-scale biomarker analysis based on 750 DNA samples from patients will be conducted using pre- and post-treatment DNA samples.

A more defined predictive biomarker as well as resistance mechanisms for both panitumumab and bevacizumab will be explored.

“This trial shows the longest survival ever reported in a first-line unresectable metastatic colorectal cancer prospective phase III trial. These findings emphasise the importance of taking into account sidedness as well as including comprehensive biomarker testing, especially for the status of the RAS gene, which is critical for all colorectal cancer patients at the time of diagnosis of metastatic disease,” said Cathy Eng, MD, FACP, FASCO, ASCO Expert in gastrointestinal cancers.

Source: ASCO

Watch Dr Yoshino's press conference here

Watch Dr Yoshino's interview on the study here

Watch Dr Cremolini comment on the study here

Watch Dr Eng comment on the study here